ScoreWhy is Hansa Biopharma AB ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -5.08% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -118.62
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 33.39%, its profits have risen by 32.5%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
105.26%
EBIT Growth (5y)
-5.08%
EBIT to Interest (avg)
-118.62
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.22
Sales to Capital Employed (avg)
0.31
Tax Ratio
0.49%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-8.23
EV to EBIT
-7.79
EV to EBITDA
-7.79
EV to Capital Employed
38.79
EV to Sales
21.26
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-498.16%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend12What is working for the Company
OPERATING CASH FLOW(Y)
Highest at SEK -549.17 MM
NET PROFIT(HY)
Higher at SEK -313.29 MM
RAW MATERIAL COST(Y)
Fallen by -16.16% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -276.62 %
DEBTORS TURNOVER RATIO(HY)
Highest at 1.79 times
NET SALES(Q)
Highest at SEK 75.99 MM
-5What is not working for the Company
INTEREST(Q)
At SEK 64.59 MM has Grown at 531.42%
CASH AND EQV(HY)
Lowest at SEK 953.15 MM
Here's what is working for Hansa Biopharma AB
Operating Cash Flow
Highest at SEK -549.17 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (SEK MM)
Net Sales
At SEK 75.99 MM has Grown at 70.18%
over average net sales of the previous four periods of SEK 44.65 MMMOJO Watch
Near term sales trend is very positive
Net Sales (SEK MM)
Net Profit
Higher at SEK -313.29 MM
than preceding 12 month period ended Dec 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (SEK MM)
Net Sales
Highest at SEK 75.99 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (SEK MM)
Debt-Equity Ratio
Lowest at -276.62 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 1.79 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -16.16% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Hansa Biopharma AB
Interest
At SEK 64.59 MM has Grown at 531.42%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (SEK MM)
Cash and Eqv
Lowest at SEK 953.15 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
